Notes from the Field: Outbreak of Severe Illness Linked to the Vitamin K Antagonist Brodifacoum and Use of Synthetic Cannabinoids — Illinois, March–April 2018
Weekly / June 1, 2018 / 67(21);607–608
Erin Moritz, PhD1,2; Connie Austin, DVM2; Michael Wahl, MD3; Carol DesLauriers, PharmD3; Livia Navon, MS2,4; Kelly Walblay, MPH2,5; Monica Hendrickson, MPH6; Angie Phillips, MSN7; Janna Kerins, VMD1,8; Audrey F. Pennington, PhD1,9; Amy M. Lavery, PhD1,10; Tharwat El Zahran, MD9,11; Judy Kauerauf, MPH2; Luke Yip, MD12; Jerry Thomas, MD12; Jennifer Layden, MD2 (View author affiliations)View suggested citation
Views equals page views plus PDF downloads
Synthetic cannabinoids, also known as K2 and spice, are heterogeneous psychoactive compounds identified as substances of abuse (1,2). On March 22, 2018, the Illinois Department of Public Health was notified by the Illinois Poison Center of four patients seen in emergency departments (EDs) during the preceding 2 weeks with unexplained bleeding and high international normalized ratios (INRs; range from 5 to >20 [normal <1.1]), indicating a clotting disorder, and reported synthetic cannabinoid use during the previous 3 days. None reported taking prescription anticoagulants or exposure to anticoagulant rodenticides. An investigation by the Illinois Department of Public Health, the Illinois Poison Center, CDC, local health departments, and law enforcement agencies was initiated to identify additional cases, ascertain epidemiologic links among patients, and implement control measures.
Requests for information regarding patients with serious bleeding and an elevated INR without a definitive etiology identified on or after February 1, 2018, were issued to Illinois EDs, emergency medical services, health care providers, local health departments, and coroners through Epi-X,* state and local health alert systems, and electronic distribution lists. Syndromic surveillance queries were developed by the Illinois Department of Public Health and implemented to identify patients evaluated at EDs and urgent care centers. Seven press releases encouraged anyone with a serious reaction after using synthetic cannabinoids to seek immediate medical attention.
Based on clinical signs and symptoms (unexplained bleeding, prolonged high INR values, and response to fresh frozen plasma and high doses of vitamin K), exposure to a long-acting vitamin K antagonist was suspected. Case definitions were developed based on signs and symptoms, synthetic cannabinoid exposure, and laboratory findings (Box). Data concerning signs and symptoms; synthetic cannabinoid use, brand, and location of purchase; and exposure to rodenticides, prescription anticoagulants, and illicit drugs were collected through patient interviews, medical chart abstraction, and Illinois Poison Center consultations. Blood samples were tested for presence of anticoagulants by high-performance liquid chromatography–tandem mass spectrometry (NMS Laboratories, Willow Grove, Pennsylvania).
As of April 25, 2018, a total of 155 cases (76 confirmed and 79 probable) had been identified; four (2.6%) patients died from major bleeding events. Median patient age was 32 years (range = 18–65 years), 115 (74%) were male, 81 (52%) were non-Hispanic white, 147 (95%) were hospitalized, and eight (5%) were treated in an ED only. The most frequently reported sign was hematuria (125; 81%); all patients reported bleeding from at least one site. INRs were elevated in all patients. All 81 (52%) analyzed clinical specimens from patients with a confirmed or probable case were positive for brodifacoum, a long-acting vitamin K antagonist used in rodenticides. Although cases clustered in two geographic areas (the Chicago area and seven neighboring counties in central Illinois), no single product source has been identified. Law enforcement is investigating the synthetic cannabinoid distribution network. Thirty-eight patients have been identified in eight other states, and CDC is conducting a multistate investigation (3). Product testing is ongoing in Illinois; some products in other states have tested positive for brodifacoum (4). Currently, the reason why brodifacoum was present in the synthetic cannabinoids is not known.
In 2017, 26 synthetic cannabinoids were listed as Schedule I substances under the Controlled Substances Act (5). However, they are often marketed as alternatives to marijuana or labeled as not for human consumption (5,6). They remain available for purchase, are relatively inexpensive, and are sometimes favored over marijuana because they are not detected in routine drug testing (2,6). The synthetic cannabinoid supply chain is unregulated, resulting in variable product compositions (2). Given the various compounds and unclear provenance, use of these products can result in unpredictable health effects (1). Stronger public messaging is needed and should target persons at risk. Engaging substance abuse services and community coalitions might improve outreach. Health care providers should consider vitamin K-dependent coagulopathy in patients with unexplained bleeding and reported or suspected synthetic cannabinoid use.
Jay S. Dalal, Hematology/Oncology, AMITA Health Center Cancer Institute, Chicago, Illinois; Robert Middleberg, NMS Laboratories, Willow Grove, Pennsylvania; Renee Funk, National Center for Environmental Health, CDC; Nirav Shah, Donald Kauerauf, Molly Lamb, Stacey Hoferka, Megan Patel, Alexandra Barger, Lori Saathoff, Dawn Nims, Illinois Department of Public Health; Kathryn Endress, Meredith Littell, Peoria City/County Health Department, Illinois; Tazewell County Health Department, Tremont, Illinois; UnityPoint Health, Peoria and Pekin, Illinois; OSF Saint Francis Medical Center, Peoria, Illinois; City of Chicago Department of Public Health, Illinois; Cook County Department of Public Health, Forest Park, Illinois.
Conflict of Interest
No conflicts of interest were reported.
Corresponding author: Erin Moritz, firstname.lastname@example.org, 217-782-2016.
1Epidemic Intelligence Service, CDC; 2Communicable Disease Control Section, Illinois Department of Public Health; 3Illinois Poison Center, Illinois Health and Hospital Association, Chicago, Illinois; 4Division of State and Local Readiness, Office of Public Health Preparedness and Response, CDC; 5Council of State and Territorial Epidemiologists Applied Epidemiology Fellowship; 6Peoria City/County Health Department, Illinois; 7Tazewell County Health Department, Tremont, Illinois; 8City of Chicago Department of Public Health, Illinois; 9Division of Environmental Health Science and Practice, National Center for Environmental Health, CDC; 10Geospatial Research Analysis and Services Program, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry, CDC; 11Emory University School of Medicine, Atlanta, Georgia; 12Division of Laboratory Sciences, National Center for Environmental Health, CDC.
- Mills B, Yepes A, Nugent K. Synthetic cannabinoids. Am J Med Sci 2015;350:59–62. CrossRefexternal icon PubMedexternal icon
- Riederer AM, Campleman SL, Carlson RG, et al. ; Toxicology Investigators Consortium (ToxIC). Acute poisonings from synthetic cannabinoids—50 U.S. toxicology investigators consortium registry sites, 2010–2015. MMWR Morb Mortal Wkly Rep 2016;65:692–5. CrossRefexternal icon PubMedexternal icon
- CDC Health Alert Network. CDC health advisory: outbreak of life-threatening coagulopathy associated with synthetic cannabinoid use. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://emergency.cdc.gov/han/han00410.asp
- CDC Clinician Outreach and Communication Activity. Outbreak alert update: potential life-threatening vitamin K-dependent antagonist coagulopathy associated with synthetic cannabinoid use. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://content.govdelivery.com/accounts/USCDC/bulletins/1eb9503external icon
- Drug Enforcement Administration. Drugs of abuse: a DEA resource guide. Washington, DC: US Department of Justice, Drug Enforcement Administration; 2017. https://www.dea.gov/pr/multimedia-library/publications/drug_of_abuse.pdfpdf iconexternal icon
- Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014;144:12–41. CrossRefexternal icon PubMedexternal icon
Bruising, nosebleeds, bleeding gums, bleeding disproportionate to injury, vomiting blood, coughing up blood, blood in urine or stool, or excessively heavy menstrual bleeding.
Elevated international normalized ratios (INRs; ≥2.0) or abnormal coagulation profile (e.g., prothrombin time in absence of INR values) for which there is no other clinical explanation, or
Detection of a long-acting anticoagulant (e.g., brodifacoum) in blood, serum, plasma, or urine, as determined by reference laboratory testing.
One or more of the clinical criteria listed above in a patient, without an alternative explanation, and with reported use of synthetic cannabinoids or unknown drugs, or with some suspicion of previous or current drug use or exposure.
One or more of the clinical criteria listed above in a patient with reported use of synthetic cannabinoids in the 3 months preceding illness onset (by patient, proxy, medical record, or health care provider), and laboratory evidence of coagulopathy as measured by meeting the first laboratory criterion listed above, or
One or more of the clinical criteria listed above, and meeting both laboratory criteria listed above, with no other explanation of results.
One or more of the clinical criteria listed above in a patient, with reported use of synthetic cannabinoids in the 3 months preceding illness onset (by patient, proxy, medical record, or health care provider), and meeting the second laboratory criterion listed above.
Suggested citation for this article: Moritz E, Austin C, Wahl M, et al. Notes from the Field: Outbreak of Severe Illness Linked to the Vitamin K Antagonist Brodifacoum and Use of Synthetic Cannabinoids — Illinois, March–April 2018. MMWR Morb Mortal Wkly Rep 2018;67:607–608. DOI: http://dx.doi.org/10.15585/mmwr.mm6721a4external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to email@example.com.